diabetestalk.net

Effects Of Insulin Plus Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) In Treating Type 1 Diabetes Mellitus: A Systematic Review And Meta-Analysis

Effects of Insulin Plus Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in Treating Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis

Effects of Insulin Plus Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in Treating Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis

Abstract
Combination therapy with insulin and glucagon-like peptide-1 receptor agonists (GLP-1RAs) has already been proven an efficient treatment option for type 2 diabetes. This combination can effectively improve glycated hemoglobin levels, cause weight loss and reduce the dosage of insulin. In addition, it can also reduce the risk of hypoglycemia. Several randomized controlled trials have confirmed that this treatment may be just as effective for type 1 diabetes mellitus (T1DM) patients. The objective of this meta-analysis was to assess the effects and efficacy of the treatment on glycemic changes, weight loss and insulin dosage in type 1 diabetes mellitus patients.
We searched Embase, PubMed and Cochrane for randomized controlled trials (no time restrictions) that investigated combined insulin and GLP-1 treatment. The main endpoints were measurements of glycated hemoglobin and changes in the weight and the dosage of insulin.
In total, 1093 were studies identified, and 7 studies were included in our meta-analysis. GLP-1 agonist and insulin combination therapy led to greater reductions in HbA1c levels [P = 0.03; mean difference −0.21; 95% confidence intervals (CI) (−0.40, 0.02)] and weight [P < 0.05; −3.53 (−4.86, 2.19)] compared to control treatments. The combination therapy did not significantly influence the daily weight-adjusted total insulin dose [P = 0.05; −0.11 (−0.23, 0)], but it did reduce the daily weight-adjusted bolus insulin dose [P = 0.001; −0.06 (−0.1, 0.02)].
Our meta-analysis supports the use of a combined therapeutic regimen of insulin an Continue reading

Rate this article
Total 1 ratings
The use of animal models in diabetes research

The use of animal models in diabetes research


The use of animal models in diabetes research
Diabetes Research Group, King's College London, London, UK
Aileen King, Diabetes Research Group, Guy's Campus, King's College London, London SE1 1UL, UK. E-mail: [email protected]
Received 2011 Aug 19; Revised 2012 Feb 10; Accepted 2012 Feb 13.
Copyright 2012 The Author. British Journal of Pharmacology 2012 The British Pharmacological Society
This article has been cited by other articles in PMC.
Diabetes is a disease characterized by a relative or absolute lack of insulin, leading to hyperglycaemia. There are two main types of diabetes: type 1 diabetes and type 2 diabetes. Type 1 diabetes is due to an autoimmune destruction of the insulin-producing pancreatic beta cells, and type 2 diabetes is caused by insulin resistance coupled by a failure of the beta cell to compensate. Animal models for type 1 diabetes range from animals with spontaneously developing autoimmune diabetes to chemical ablation of the pancreatic beta cells. Type 2 diabetes is modelled in both obese and non-obese animal models with varying degrees of insulin resistance and beta cell failure. This review outlines some of the models currently used in diabetes research. In addition, the use of transgenic and knock-out mouse models is discussed. Ideally, more than one animal model should be used to represent the diversity seen in human diabetic patients.
This paper is the latest in a series of publications on the use of animal models in pharmacology research. Readers might be interested in the previous papers.
Robinson V (2009). Less is more: reducin Continue reading

Most People with Diabetes Should Stop Iron Supplements

Most People with Diabetes Should Stop Iron Supplements


February 16, 2017 by David Mendosa
When you have too much iron in your blood or stored elsewhere in your body might be why your blood glucose level is above normal. In fact, too much iron can even be why you got diabetes. Yet about one out of every five Americans regularly takes an iron supplement.
For years researchers have suspected that when your body accumulates too much iron you are at risk of a host of diseases, according to Berkeley Wellness . In addition to diabetes, iron overload is linked to colorectal cancer, high blood pressure, and hardening of the arteries, as well as to strokes, Alzheimers Disease, and Parkinsons disease.
But only now do we have studies demonstrating the connection between excess iron and diabetes.
Even mildly elevated body iron contributes to the prevalence and incidence of type 2 diabetes, states the news release from the University of Eastern Finland announcing the publication of these studies.
One of these recent studies looked at why men are more likely to have diabetes than women. The International Diabetes Federation estimated that 215.2 million men and 199.5 million women a difference of more than 15 million people had diabetes worldwide in 2015.
Only the abstract of this study, Gender difference in type 2 diabetes and the role of body iron stores , is free online. But the lead author, Alex Aregbesola, M.D., Ph.D., emailed me the full text upon my request. Dr. Aregbesola is a researcher at the Institute of Public Health and Clinical Nutrition, University of Eastern Finland. This study, which includes a prospectiv Continue reading

Type 2 Diabetes: Why Sleep Quality Matters

Type 2 Diabetes: Why Sleep Quality Matters


Type 2 Diabetes: Why Sleep Quality Matters
A good nights sleep can help manage blood sugar, blood pressure, and insulin resistance. Heres how to get high-quality sleep.
Medically Reviewed by Rosalyn Carson-DeWitt, MD
Sign Up for Our Living with Diabetes Newsletter
Sign up for more FREE Everyday Health newsletters .
Most people with type 2 diabetes know that making certain daily lifestyle choices such as eating a healthy diet and getting regular exercise are essential to managing the condition. But what about getting good sleep?
Experts say that quality sleep is just as essential, and that poor sleep negatively affects many health issues related to type 2 diabetes , including blood sugar levels, according to a consensus statement issued by the American Association of Clinical Endocrinologists (AACE) and published in January 2017 in the journal Endocrine Practice .
Poor sleep is very common with type 2 diabetes, says Daniel Einhorn, MD , a clinical endocrinologist, medical director of the Scripps Whittier Diabetes Institute in San Diego, and past president of the AACE. This can have an adverse effect on all aspects of [the condition].
Both the quality and quantity of sleep matter when it comes to type 2 diabetes. According to multiple studies over the past two decades, poor sleep can disrupt a number of factors related to type 2 diabetes, including:
Sleep deprivation affects the bodys ability to use glucose efficiently, which can increase the risk for type 2 diabetes. And people with sleep problems difficulty falling or staying asleep, sleeping fewer than 5 to 6 h Continue reading

Apple Stock Prediction: Gadgets For Diabetes Management Could Provide Apple A New Source Of Revenue

Apple Stock Prediction: Gadgets For Diabetes Management Could Provide Apple A New Source Of Revenue

The article was written by Motek Moyen Research Seeking Alpha’s #1 Writer on Long Ideas and #2 in Technology – Senior Analyst at I Know First.
AAPL Stock Prediction
Summary:
Apple is reportedly testing a smart band for blood glucose level monitoring. The said smart band will allegedly work as an add-on for the Apple Watch.
A smart band for diabetics to continuously monitor their blood sugar level offers plenty of economic potential for Apple.
There are more than 422 million people around the world that suffers from diabetes. That’s a huge market for wearable blood sugar tracker.
Selling diabetes-focus smart bands helps Apple lessen its dependency on iPhone sales.
AAPL has strong buy signals from the market trend algorithmic forecasts of I Know First.
Apple (AAPL) is set to make some money on its upcoming smart band for blood sugar level tracking. CNBC reported that Tim Cook himself is testing a non-invasive glucose monitoring device. I appreciate this latest foray for diabetes management. There’s more than 422 million people around the world that suffers from diabetes. Apple could sell a $99 or $149 non-invasive blood sugar level tracker and I expect it to easily sell 20 million units per year.
Look at the chart below that the World Health Organization (WHO) published last year. WHO emphasized that the population of diabetes-stricken people are on the rise too. The increasing sedentary lifestyle of people will continue to contribute to the diabetes epidemic.
Apple’s entry as a vendor that will help diabetes sufferers is therefore judicious. The future economic con Continue reading

No more pages to load

Popular Articles

Related Articles